Scholarlink

<p>Hereditary breast and ovarian cancer syndrome (HBOC) is principally caused by germline mutations in <i>BRCA1</i> and <i>BRCA2</i>. However, most women with HBOC are undiagnosed, and some patients meeting clinical criteria for HBOC will have no identifiable mutation after genetic testing. Here, we deploy a lasso-based model to combine serum miRNA profiles with clinical data to identify women at elevated risk for ovarian cancer among a population of 1831 individuals enrolled in an institutional biobank. The miRNA and metadata variables are mapped to two-dimensional space using lasso, after which a linear classification model is trained to estimate “<i>BRCA</i>ness” and long-term risk of cancer. After tenfold cross-validation, the method offers a <i>BRCA</i> prediction AUC score of 0.98 (95% CI 0.94–1.0) and generalizes across subgroups stratified by age, cancer history, and racial/ethnic group. To demonstrate the clinical relevance of this phenotype, we use the lasso-based model to assess 5-year ovarian cancer risk among an independent cohort of 1044 subjects agnostic to genetic testing results enrolled in a randomized clinical trial. In this unselected population, the output of the lasso-based model strongly correlates to the log 5-year relative risk of ovarian cancer (R = 0.93, 95% CI 0.83–0.97, <i>p</i> &lt; 0.0001). When the model was used to predict future onset of ovarian cancer directly, the AUC offered was AUC = 0.75 (95% CI 0.70–0.78). Together, these data suggest the proposed model is a predictor of future ovarian cancer risk.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A lasso-based model combining miRNA and clinical variables predicts future risk of breast and ovarian cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月24日

查看全文
  • James W. Webber,
  • Laura Wollborn,
  • Sudhanshu Mishra,
  • Stephanie Alimena,
  • Bryanna Testino,
  • Konrad Stawiski,
  • Wojciech Fendler,
  • Dipanjan Chowdhury,
  • Kevin M. Elias

摘要

Hereditary breast and ovarian cancer syndrome (HBOC) is principally caused by germline mutations in BRCA1 and BRCA2. However, most women with HBOC are undiagnosed, and some patients meeting clinical criteria for HBOC will have no identifiable mutation after genetic testing. Here, we deploy a lasso-based model to combine serum miRNA profiles with clinical data to identify women at elevated risk for ovarian cancer among a population of 1831 individuals enrolled in an institutional biobank. The miRNA and metadata variables are mapped to two-dimensional space using lasso, after which a linear classification model is trained to estimate “BRCAness” and long-term risk of cancer. After tenfold cross-validation, the method offers a BRCA prediction AUC score of 0.98 (95% CI 0.94–1.0) and generalizes across subgroups stratified by age, cancer history, and racial/ethnic group. To demonstrate the clinical relevance of this phenotype, we use the lasso-based model to assess 5-year ovarian cancer risk among an independent cohort of 1044 subjects agnostic to genetic testing results enrolled in a randomized clinical trial. In this unselected population, the output of the lasso-based model strongly correlates to the log 5-year relative risk of ovarian cancer (R = 0.93, 95% CI 0.83–0.97, p < 0.0001). When the model was used to predict future onset of ovarian cancer directly, the AUC offered was AUC = 0.75 (95% CI 0.70–0.78). Together, these data suggest the proposed model is a predictor of future ovarian cancer risk.